PT-150 is under clinical development by Palisades Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PT-150’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 30 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 30 Dec 2021 increased PT-150’s Phase Transition Success Rate (PTSR) for Ovarian Cancer, and increased PTSR for Pancreatic Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PT-150 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PT-150 overview

PT-150 is under development for the treatment of opiod nicotine addiction, alcohol addiction, pancreatic cancer, glioblastoma, treatment-resistant prostate cancer, ovarian cancer, TNBC and Covid-19. It acts by targeting GR translocation and corticosterone-induced GR translocation. It was also under development for the treatment of psychotic major depression, breast cancer and ovarian cancer. The drug candidate in combination with chemo therapeutics used as a chemo sensetizer.

Quick View PT-150 LOA Data

Report Segments
  • Innovator
Drug Name
  • PT-150
Administration Pathway
Therapeutic Areas
  • Central Nervous System
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.